Surfix is proud to announce the launch of a groundbreaking project supported by PhotonDelta

Surfix is proud to announce the launch of a groundbreaking project entitled “Unparalleled Sensitivity: Unlocking High-Volume Demand of Photonic Biosensors for Point-of-Care Testing (POCT),” supported by PhotonDelta as part of the National Growth Fund (NGF) Programme.

This initiative takes a significant step toward realizing the transformative potential of photonic technology in diagnostics and disease monitoring. Enhancements to the Surfix photonic diagnostics platform will enable support for a broader range of biomarkers and applications.

Key highlights of the project include:

• Quality Assurance: Development of rigorous QC testing for photonic chips to ensure compliance with in vitro diagnostic market regulations.
• Clinical Relevance: Advancements in photonic chip features designed to meet the specific needs of daily clinical practice.

This effort aligns closely with PhotonDelta’s vision to establish the Netherlands as Europe’s leading hub for integrated photonics. By addressing critical industry challenges, the project aims to drive innovation and impact healthcare practices.

PhotonDelta is a prominent example of how the National Growth Fund is supporting transformative technologies. By funding initiatives like PhotonDelta, the NGF is fostering economic growth and helping the Netherlands maintain its competitive edge in high-tech industries.

Stay tuned for updates as progress unfolds!